Skip to content

April 30, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Commercial
Pfizer protects $6.4bn heart disease blockbuster from generics, for now

Commercial

Pfizer protects $6.4bn heart disease blockbuster from generics, for now

Pharmaceutical Technology

Pfizer's Vyndamax will be free from generics competition until 2031 in a boost to the company's revenue streams.

Read full story

pharminent April 29, 2026 (Last updated: April 30, 2026)

Pharmaceutical Technology

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Read full story

Post navigation

Previous: Chiesi to buy KalVista in $1.9B deal for rare disease drug

Next: Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

Related Stories

Commercial

Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth

pharminent April 30, 2026

Commercial

Regeneron Q1 2026 net income falls 10% to $727m

pharminent April 30, 2026

Commercial

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

pharminent April 29, 2026

You May Have Missed

Commercial

Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth

pharminent April 30, 2026

M&A / Deals

Teva makes its first M&A play in years, buying Emalex

pharminent April 30, 2026

Pipeline

AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio

pharminent April 30, 2026

Clinical Data

GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints

pharminent April 30, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.